International
The Morning Science

What science found today

‹
 

Research

GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia

MedPage Today ·

GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia

The Brief

  • An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycaemic events after bariatric surgery in the phase III LUCIDITY trial.
  • The reported baseline mean was 2.39 hypoglycaemic events per period; the source text is cut off before the period and the post-treatment figures are not given.
  • The results were presented at ObesityWeek in National Harbor, Md., and described by MedPage Today as clinically meaningful.

Why it matters

Post-bariatric hypoglycaemia is a recurring complication with few targeted treatments, so a phase III result with a significant reduction in events is relevant to clinicians and researchers in obesity and metabolic medicine. The drug is still investigational and not approved.

Who’s affected

  • clinicians and researchers treating patients after bariatric surgery
  • patients who have had bariatric surgery and experience hypoglycaemia

(MedPage Today) -- NATIONAL HARBOR, Md. -- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial. From a baseline mean of 2.39 events per...

How do you feel about this?

0 Comments

    GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia – The Morning Science